EZH2 and B-cell non-Hodgkin lymphoma: A recent study suggests that tazemetostat may activate the anti-lymphoma response and promote T-cell recruitment by upregulating CCL17 expression in B-cell lymphoma cells, which provides a basis for its use in combination with immunotherapy.207 CD8+ effector T (Teff) cell development and polyfunctionality are disrupted and the propensity for terminal differentiation is increased after conditional knockout or shRNA-mediated deletion of Ezh2.